We have another fuzzy snapshot of clinical trial data on Gileads remdesivir in coronavirus patients, and at first glance this one looks bleak for the most advanced therapy now in the clinic for Covid-19.<\/p>\n
The Financial Times and STAT both reported on an abstract of the Chinese study, this one using a control group that appeared temporarily on the WHO site after it was posted accidentally. Its still not been peer reviewed, but Salim Syed at Mizuho summarized the numbers:Of the 237 patients that were studied in the trial, 158 were on remdesivir, and 79 were on control, and remdesivir did not produce a difference in mortality at 28 days (13.9% for remdesivir vs 12.8% for control).Taken at face value, thats a nasty failure. The stock dropped 4% this afternoon. BUT you cant take it at face value, as Gilead pointed out in a followup statement.<\/p>\n
Unlock this article along with other benefits by subscribing to one of our paid plans. <\/p>\n
SUBSCRIBE SIGN IN <\/p>\n
<\/p>\n
The rest is here: <\/p>\n
Sangamo ties up with a newcomer in the cell therapy field; LabCorp wins FDA authorization of latest Covid-19 test - Endpoints News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" We have another fuzzy snapshot of clinical trial data on Gileads remdesivir in coronavirus patients, and at first glance this one looks bleak for the most advanced therapy now in the clinic for Covid-19. The Financial Times and STAT both reported on an abstract of the Chinese study, this one using a control group that appeared temporarily on the WHO site after it was posted accidentally. Continue reading